As Prevention

Terrence Higgins Trust gives away thousands of HIV home testing kits

published: May, 30, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , African, Caribbean and Black, Gay Men, Treatment Guidelines -including when to start, General Health, Health, International , Treatment, Media, Revolving Door, Guest Authors

From Pink News, Benjamin Butterworth reports on Terrence Higgins Trust's bid to reduce the number of Brits who are unaware of their status.

Terrence Higgins Trust gives away thousands of HIV home testing kits

A charity is offering thousands of HIV home testing kits for free. Terrence Higgins Trust, the HIV and sexual health charity, is giving away 2,000 kits in a bid to reduce the number of Brits who are unaware of their status. The charity reports that one in seven people who are HIV-positive do not know their status. Gay and bisexual men, along with black African men and women, are the most-likely to be affectived by HIV. The home-testing kits can identify a person’s results in just 60 sec

The 'Charlie Sheen effect': surge seen in HIV test sales

published: May, 29, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Treatment Guidelines -including when to start, Health, International , Treatment, Media, Revolving Door, Guest Authors

"In fact, the researchers estimated that sales of home HIV testing kits were nearly eight times greater around the time of Sheen's announcement..." From Live Science, Rachael Rettner reports

The 'Charlie Sheen effect': surge seen in HIV test sales

Actor Charlie Sheen in April 2013 Credit: Michael Buckner/Getty Images Actor Charlie Sheen's disclosure that he is HIV positive appears to have had a striking effect on sales of home HIV testing kits, a new study suggests. Researchers found that, after Sheen announced he had HIV on Nov. 17, 2015, sales of home HIV testing kits doubled in the United States — from about 3,500 kits per week before the announcement, to 7,000 kits the week of the announcement. And this boost in sales continue

African-American men who have sex with men less likely to be on HIV treatment in the U. S.

published: May, 29, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, African, Caribbean and Black, As Prevention , Treatment Guidelines -including when to start, Current Affairs, Health, International , Treatment, Revolving Door, Guest Authors

From TheBody.com, Barbara Jungwirth reports on the findings of the National HIV Behavioral Surveillance (NHBS) project.

African-American men who have sex with men less likely to be on HIV treatment in the U. S.

African-American men who have sex with men (MSM) are significantly less likely to be taking antiretroviral medications than are their white counterparts, an analysis of multi-year data found. The study was published in The Journal of Infectious Diseases. The National HIV Behavioral Surveillance (NHBS) project has surveyed groups at risk for seroconverting (such as MSM or intravenous drug users) in three-year cycles since 2003. Interviewees are asked about their HIV testing and treatment hist

Yes, drug laws absolutely hurt HIV prevention and treatment, study shows.

published: May, 26, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , African, Caribbean and Black, Gay Men, Treatment Guidelines -including when to start, Women, Health, International , Legal, Treatment, Revolving Door, Guest Authors

"In the five countries where the HIV epidemic is now being driven by injection drug use—China, Malaysia, Russia, Ukraine and Vietnam—drug users are the least likely to know their HIV status and be taking HIV medications." From Newsweek, Jessica Wapner

Yes, drug laws absolutely hurt HIV prevention and treatment, study shows.

To read the complete story by Jessica Wapner, visit Newsweek, here. When it comes to HIV risk factors, IV drug use is catching up to sex. Among people who inject drugs, an estimated 13 percent have HIV. About 30 percent of new infections outside of sub-Saharan Africa are the result of sticking dirty needles into vulnerable veins. In 2014, more than half of new HIV infections in Eastern Europe and central Asia were due to drugs. In the Middle East and northern Africa, nearly one-third of inf

Federal announcement on new pharmaceutical policy could signal improvements long hoped for by patient groups and healthcare providers. Here's how.

published: May, 24, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Health, Treatment, Media, Revolving Door, Guest Authors

Jack Mohr of CTAC on how Philpott's proposed changes might impact drug prices and access for people living with HIV.

Federal announcement on new pharmaceutical policy could signal improvements long hoped for by patient groups and healthcare providers. Here's how.

On May 16th, Health Minister Jane Philpott announced a suite of proposed changes to Canadian pharmaceutical policy. While many of these changes are merely sketched out rather than fully realized, they represent potential fixes to the Canadian healthcare system that patient groups and healthcare providers have been hoping for. For people living with HIV, these updates could mean a future with better and more comprehensive access to necessary medications. Expediting the Drug Approval Process T

Early doses, late doses, extra doses, missed doses: What's the risk? An HIV Doc Responds

published: May, 23, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Treatment Guidelines -including when to start, Health, International , Treatment, Revolving Door, Guest Authors

From TheBody.com, renowned HIV physician Joel Gallant, M.D., M.P.H., fields questions about treatment adherence.

Early doses, late doses, extra doses, missed doses: What's the risk? An HIV Doc Responds

To read the complete article by Myles Helfand, visit The Body, here. Adherence imperfection is one of the more common concerns TheBody.com hears about from people taking once-daily HIV treatment regimens. They want to know: What's the penalty of a missed HIV medication dose? How much room is there for error if a person is off by an hour, or three hours, or an entire day? When it comes to meds, how human can a person get away with being? On his personal Tumblr, Joel Gallant, M.D., M.P.H.,

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

published: May, 17, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Health, Treatment, Revolving Door, Guest Authors

Gilead's first TAF-based single tablet regimen demonstrates high efficacy with improved renal and bone parameters compared to TDF-based regimens.

Multiple provinces and territories demonstrate leadership in the treatment of HIV/AIDS by providing access to GENVOYA®

MISSISSAUGA, ON, May 4, 2017 /CNW/ - Gilead Sciences Canada, Inc. today announced that GENVOYA® tablets, for the treatment of HIV-1 infection, is now listed in multiple provinces and territories including, Ontario, Alberta, Quebec and Yukon, as well as in the Non-Insured Health Benefits (NIHB) Drug Plan for First Nations and Inuit. GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of h

CTAC talks! Treating the sickest first: exploring Hepatitis C treatment in Canada

published: May, 17, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, Hep B and C, As Prevention , Gay Men, Treatment Guidelines -including when to start, Women, Health, Treatment, Media, Opinion Pieces, Revolving Door, Guest Authors

CTAC Talks is an innovative web series highlighting treatment access issues and solutions for Canadians living with HIV and Viral Hepatitis.

CTAC talks! Treating the sickest first: exploring Hepatitis C treatment in Canada

CTAC's expert guests, Dr. Lisa Barrett, Carrielynn Lund and Dr. Jordan Feld explore the current landscape of Hepatitis C treatment in Canada; a cure is available but there are significant treatment access barriers. For more information, visit the Canadian Treatment Access Council (CTAC), here.

Ontario HIV Treatment Network (OHTN) endorses U=U.

published: May, 17, 2017 Written by // Ontario HIV Treatment Network - Research Categories // Social Media, OHTN OHTN/PositiveLite.com, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Research, Sexual Health, Health, Treatment

The Ontario HIV Treatment Network: "Acting on this knowledge will drive good public policy and clinical practice – encouraging prompt access to testing, treatment and support, as well as dramatically reducing HIV stigma."

Ontario HIV Treatment Network (OHTN) endorses U=U.

The "Undetectable = Untransmittable" Campaign (U=U) is an international movement. It unites communities of people living with HIV, service organizations and leading HIV researchers in support of a clear, evidence-based consensus statement about the power of effective antiretroviral treatment to prevent the sexual transmission of HIV. The Ontario HIV Treatment Network endorsed the U=U consensus, as follows, on May 15, 2017: The Ontario HIV Treatment Network (OHTN) is funded by the Ministry

‘A near normal lifespan for people with HIV?’ For whom is this true - and who misses out?

published: May, 15, 2017 Written by // Megan DePutter Categories // Aging, Social Media, As Prevention , Treatment Guidelines -including when to start, General Health, Health, International , Smoking Cessation , Treatment, Megan DePutter, Opinion Pieces

Megan DePutter: "We can’t ignore these vulnerabilities that can put individuals more at risk both for acquiring HIV, getting diagnosed late, or struggling to adhere to the medication."

‘A near normal lifespan for people with HIV?’ For whom is this true - and who misses out?

Yesterday, the Lancet published a study titled ‘Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies’. This study found that ‘even in the late ART era, survival during the first three years of ART continues to improve.’ In fact, the authors found that ‘between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about nine years in women and ten years in men.’ The authors con

Is this the beginning of the end for HIV?

published: May, 11, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , African, Caribbean and Black, Gay Men, Treatment Guidelines -including when to start, Current Affairs, Sexual Health, International , Treatment, Living with HIV, Opinion Pieces, Revolving Door, Guest Authors

From FS Magazine, Matthew Hodson writes on the importance of getting PrEP to those who need it.

Is this the beginning of the end for HIV?

The end of year reviews of 2016 were pretty damning. Bowie, Prince and George Michael led a long list of musical heroes who left us. Brexit in the UK and Trump in the US upset the pollsters and divided both nations. Worldwide, there was a succession of murderous atrocities committed, not least a bloody attack on a gay nightclub in Miami. And Princess Leia died. And then her mum died too. But just before Christmas there was one bit of good news. 56 Dean Street, the busiest sexual health clinic

Are women prepared for HIV PrEP?

published: May, 05, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, Dating, As Prevention , African, Caribbean and Black, Treatment Guidelines -including when to start, General Health, Research, Women, International , Treatment, Lifestyle, Revolving Door, Guest Authors

From KALW.org, Chloe Lessard: "some women and trans folks are wondering why a drug that could potentially save their lives hasn’t been aggressively promoted in their communities."

Are women prepared for HIV PrEP?

To read the complete article by Chloe Lessard, visit KALW.org, here. Did you know that you can take a drug to reduce your risk of getting HIV? If you’re a gay man, you’ve probably heard of it. It’s a daily regimen called PrEP, or pre-exposure prophylaxis. Maybe you’ve even seen ads for it on BART trains or clinic brochures, usually targeting men who sleep with other men. But PrEP doesn’t only benefit men, and some women and trans folks are wondering why a drug that could potential

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

published: May, 02, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Treatment Guidelines -including when to start, Research, Health, Treatment, CATIE - HIV and Hep C Info Resource

Sean R. Hosein of CATIE reports on research in Vancouver that attempted to study the relative impact that ART, harm reduction or both can have on the spread of HIV.

Research finds that harm reduction and ART helped to reduce the spread of HIV in Vancouver

In clinical trials, the early initiation of HIV treatment (ART) stabilizes the immune system and significantly reduces the risk of developing AIDS-related infections and cancers. This benefit of ART is so profound that researchers increasingly expect that many ART users will live into their senior years. Key to reaping the benefit of ART is achieving an undetectable level of HIV in the blood (viral load) and maintaining it through daily use of ART and regular checkups and laboratory monitori

A quarter of people taking antiretroviral therapy in Kenya have exhausted current treatment options

published: April, 28, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, African, Caribbean and Black, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Health, International , Treatment, Media, Population Specific , Revolving Door, Guest Authors

From AIDSmap, Michael Carter reports: "If anything, the investigators believe their study may have under-estimated the prevalence of second-line treatment failure."

A quarter of people taking antiretroviral therapy in Kenya have exhausted current treatment options

Affordable third-line antiretrovirals are urgently needed in resource-limited settings, according to research conducted in Kenya and published in the online edition of AIDS. The study showed that a quarter of patients had exhausted current treatment options and only 18% had virus that was fully susceptible to the three main classes of anti-HIV drugs. “This study in the Kenyan national antiretroviral therapy (ART) program suggests that about 27% of patients with second-line failure are in

Scotland says ‘yes’ to PrEP

published: April, 20, 2017 Written by // Alex Sparrowhawk Categories // Social Media, As Prevention , Gay Men, Treatment Guidelines -including when to start, Sexual Health, International , Treatment, Media, Alex Sparrowhawk

Alex Sparrowhawk: "The news today exacerbates a postcode lottery that already exists in the UK when it comes to sexual health and the impact that has on the communities living with and affected by HIV."

Scotland says ‘yes’ to PrEP

In just a couple of weeks we will also have an announcement in Wales – let’s hope it is as positive. I’m annoyed at my ignorance but I don’t even know what’s happening in Northern Ireland and a quick ‘Google’ isn’t answering the question. Meanwhile in England we’re still awaiting the start date of another trial – although in reaction to the news today a statement was released:  "Considerable progress has been made in preparing for the HIV pre-exposure prophylaxis (PrEP)

<<  1 2 3 4 [56 7 8 9  >>